Madgril Severe Renal ---- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function
Start: 2024-03-05
Primary End: 2024-11-30
Study Completion: 2024-12-31
Enrollment: 28